1. Clinical Overview
Remogliflozin Etabonate is a selective, competitive, and reversible inhibitor of the sodium-glucose co-transporter 2 (SGLT2) located in the proximal convoluted tubule of the nephron. It is a prodrug of the active metabolite, remogliflozin. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It promotes glucosuria by reducing renal glucose reabsorption, leading to a reduction in plasma glucose levels and HbA1c.
| Onset | Duration | Bioavailability |
|---|---|---|
| Glucosuric effect begins within 1-2 hours of oral administration. | Approximately 24 hours, supporting once-daily dosing. | Approximately 40% for the prodrug (Remogliflozin Etabonate). The active metabolite, remogliflozin, has a bioavailability of nearly 100%. |
2. Mechanism of Action
Remogliflozin Etabonate is a prodrug that is rapidly converted to remogliflozin, a potent and selective inhibitor of SGLT2. SGLT2 is the primary transporter responsible for reabsorbing approximately 90% of filtered glucose from the renal tubule back into the bloodstream. By inhibiting SGLT2, remogliflozin reduces the renal threshold for glucose (RTG), leading to increased excretion of glucose in the urine (glucosuria). This mechanism is independent of insulin secretion and action.
3. Indications & Uses
- Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.
4. Dosage & Administration
Adult Dosage: 100 mg orally once daily, taken with or without food. The dose can be taken in the morning.
Administration: Tablet should be swallowed whole with a glass of water. Can be taken at any time of the day, but preferably at the same time each day. Maintain adequate fluid intake to prevent volume depletion.
5. Side Effects
Common side effects may include:
- Increased urination
- Genital mycotic infections (e.g., vulvovaginal candidiasis, balanitis)
- Urinary tract infections
- Increased thirst
- Headache
- Dizziness (related to volume depletion)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Insulin or Insulin Secretagogues (Sulfonylureas, Meglitinides) | Increased risk of hypoglycemia. Dose reduction of insulin/secretagogue may be required. | Major |
| Loop Diuretics (e.g., Furosemide) | Additive diuretic effect, increasing the risk of volume depletion and hypotension. | Moderate |
| Other SGLT2 Inhibitors | No therapeutic benefit from combined use; increased risk of adverse effects. | Contraindicated |
| UGT Inducers (e.g., Rifampicin) | May decrease systemic exposure of remogliflozin, potentially reducing efficacy. | Moderate |
| Antihypertensive Agents | Potentiation of blood pressure-lowering effects, risk of hypotension. | Moderate |
7. Patient Counselling
- DO take the tablet once daily, as prescribed, with or without food.
- DO maintain adequate fluid intake to prevent dehydration.
- DO monitor your blood glucose levels as advised by your doctor.
- DO inform your doctor about any other medications you are taking.
- DO practice good personal hygiene to reduce the risk of genital infections.
- DONT use this medicine if you are pregnant, planning pregnancy, or breastfeeding without consulting your doctor.
- DONT skip meals if you are also on insulin or medicines like sulfonylureas.
- DONT start this medicine if you have severe kidney problems.
8. Toxicology & Storage
Overdose: Expected symptoms would be related to its pharmacologic effects: severe volume depletion (hypotension, tachycardia, dizziness), hypoglycemia (if combined with other anti-diabetic agents), electrolyte imbalances (hyponatremia, hyperkalemia), and severe polyuria.
Storage: Store below 30°C. Protect from light and moisture. Keep the tablet in the original blister pack or container until use. Keep out of reach of children.